CA2461631A1 - Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques - Google Patents

Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques Download PDF

Info

Publication number
CA2461631A1
CA2461631A1 CA002461631A CA2461631A CA2461631A1 CA 2461631 A1 CA2461631 A1 CA 2461631A1 CA 002461631 A CA002461631 A CA 002461631A CA 2461631 A CA2461631 A CA 2461631A CA 2461631 A1 CA2461631 A1 CA 2461631A1
Authority
CA
Canada
Prior art keywords
antigen
tumor
binds
mammal
tumor associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002461631A
Other languages
English (en)
Inventor
David Jackson
Linda Nardone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elusys Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2461631A1 publication Critical patent/CA2461631A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à des molécules bispécifiques présentant une première partie de reconnaissance de l'antigène qui fixe un récepteur de type C3b (connu comme récepteur de complément 1 (CR1) ou CD35 chez les primates), et une seconde partie de reconnaissance de l'antigène qui fixe un antigène associé à une tumeur et présent dans la circulation d'un mammifère. L'invention se rapporte également à des méthodes d'utilisation des molécules bispécifiques pour éliminer de la circulation d'un mammifère les antigènes associés à une tumeur libérés. En outre, l'invention se rapporte à des méthodes d'utilisation de molécules bispécifiques pour le diagnostic et le traitement du cancer.
CA002461631A 2001-09-28 2002-09-27 Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques Abandoned CA2461631A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32573201P 2001-09-28 2001-09-28
US60/325,732 2001-09-28
PCT/US2002/031020 WO2003026490A2 (fr) 2001-09-28 2002-09-27 Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques

Publications (1)

Publication Number Publication Date
CA2461631A1 true CA2461631A1 (fr) 2003-04-03

Family

ID=23269190

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002461631A Abandoned CA2461631A1 (fr) 2001-09-28 2002-09-27 Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques

Country Status (4)

Country Link
EP (1) EP1487487A2 (fr)
JP (1) JP2005510470A (fr)
CA (1) CA2461631A1 (fr)
WO (1) WO2003026490A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20060147457A1 (en) * 2002-05-13 2006-07-06 Porter James P Purified composition of bispecific molecules and methods of production
CA2543830A1 (fr) * 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detection d'anticorps anti-therapeutique humain
AU2005302312A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of CR1-binding molecules in clearance and induction of immune responses
RU2007133660A (ru) * 2005-02-09 2009-03-20 Дженентек, Инк. (Us) Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007146968A2 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur
EP2365003A1 (fr) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC Produits d'immunothérapie de CD37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
CA2981312C (fr) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Regions constantes de chaines lourdes presentant une liaison reduite aux recepteurs fc gamma
EP3352760B1 (fr) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Polypeptides de liaison à cd3
LT3353212T (lt) * 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela

Also Published As

Publication number Publication date
JP2005510470A (ja) 2005-04-21
EP1487487A2 (fr) 2004-12-22
WO2003026490A2 (fr) 2003-04-03
WO2003026490A3 (fr) 2004-10-21

Similar Documents

Publication Publication Date Title
JP5185815B2 (ja) 抗ｃｄ７１モノクローナル抗体および悪性腫瘍細胞を治療するためのその使用
US10246516B2 (en) Anti-La antibodies and their use for immunotargeting
JP6389166B2 (ja) 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
CN109071642B (zh) 连接蛋白(Cx)43半通道结合抗体及其用途
US20230190796A1 (en) Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
ES2534288T3 (es) Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
AU2012277784B2 (en) Antibodies against prostate-specific stem cell antigen and use thereof
AU2017382883B2 (en) Human monoclonal antibodies specific for FLT3 and uses thereof
US20120027763A1 (en) Antibody for Targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
AU5787601A (en) Composition for inhibiting macrophage activity
JP2022519377A (ja) がんのバイオマーカーとしてのｉｌ－４ｒ
CA2461631A1 (fr) Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques
US20250270320A1 (en) Anti-pd-1 antibody and uses thereof
US20090053136A1 (en) Methods of Therapy and Diagnosis Using Immunotargeting of CD84Hy1-expressing Cells
EP4346887A1 (fr) Molécules de liaison au récepteur des chimiokines 6 à motif c-x-c (cxcr6), et leurs procédés d'utilisation
CN119708240A (zh) 抗人癌胚抗原相关的细胞粘附分子5的抗体、其制备方法及应用
CN116535509B (zh) 抗CD79b抗体、其制备方法及其应用
WO2024255692A1 (fr) Anticorps ciblant le facteur de croissance épidermique humain 3, son procédé de préparation et son utilisation
JP2016013104A (ja) 抗イヌｃｄ２０モノクローナル抗体又は抗体フラグメント、キット、診断方法、治療用組成物、治療方法、核酸、ベクター、キメラ抗原受容体及びｔ細胞
US12595307B2 (en) Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
CN113735973B (zh) 一种抗SIRPα抗体及其应用
AU2002340069A1 (en) Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
JP2026023561A (ja) Ｖｓｉｇ２に特異的に結合する物質を含む癌の治療剤
WO2026002282A1 (fr) Nanocorps ciblant et/ou se liant de manière spécifique à b7-h3

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060927